LivaNova LIVN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Cardiopulmonary | $817.72M+4.1% | $785.39M+3.3% | $760.48M+4.2% | $729.5M+3.6% | $703.94M+3.0% | |
| Neuromodulation | $605.71M+2.2% | $592.81M+2.6% | $577.7M+1.7% | $568.04M+1.6% | $559.24M+0.9% | |
| Operating Income by Business | ||||||
| Cardiopulmonary | $113.68M+5.0% | $108.3M+6.6% | $101.64M+3.1% | $98.61M— | —— | |
| Neuromodulation | $207.28M-3.8% | $215.47M+3.2% | $208.84M+3.3% | $202.19M— | —— | |
| Total Assets by Business | ||||||
| Cardiopulmonary | $4.12B+2.6% | $4.02B+3.7% | $3.87B+1.4% | $3.82B+2.1% | $3.74B-0.1% | |
| Neuromodulation | $2.57B+0.3% | $2.56B0.0% | $2.56B+0.2% | $2.56B-0.1% | $2.56B-0.4% | |
| Selling, general, and administrative by Business | ||||||
| Cardiopulmonary | $231.15M+0.6% | $229.78M-5.6% | $243.37M+3.9% | $234.12M+2.2% | $229.05M+3.5% | |
| Neuromodulation | $207.65M+2.5% | $202.6M+1.8% | $198.93M+2.3% | $194.52M+2.6% | $189.53M+1.0% | |
| Cost of Sales by Business | ||||||
| Cardiopulmonary | $397.72M+4.2% | $381.71M+3.5% | $368.94M+4.9% | $351.83M+2.6% | $342.97M+2.6% | |
| Neuromodulation | $56.65M+1.5% | $55.82M-2.4% | $57.17M+2.3% | $55.86M+4.8% | $53.29M+6.1% | |
| R&D by Business | ||||||
| Cardiopulmonary | $71.49M+8.7% | $65.74M+7.5% | $61.18M+10.0% | $55.63M+5.0% | $53M+0.2% | |
| Neuromodulation | $134.13M+12.8% | $118.92M+5.5% | $112.76M-2.3% | $115.46M0.0% | $115.44M-4.6% | |
| 3T litigation provision by Business | ||||||
| Cardiopulmonary | $3.69M-15.8% | $4.38M-39.7% | $7.26M-35.3% | $11.22M-19.9% | $14M-28.9% | |
| Neuromodulation | $0— | $0— | $0— | $0— | $0— | |
| CapEx by Business | ||||||
| Cardiopulmonary | $49.75M+11.8% | $44.51M+35.4% | $32.86M+6.9% | $30.75M+4.2% | $29.51M+5.1% | |
| Neuromodulation | $22.64M+43.0% | $15.83M+23.2% | $12.85M+35.4% | $9.49M+58.2% | $6M+41.4% | |
| Goodwill by Business | ||||||
| Cardiopulmonary | $1.57B+1.5% | $1.54B+2.9% | $1.5B+0.6% | $1.49B+1.8% | $1.46B-0.7% | |
| Neuromodulation | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | $1.6B0.0% | |
| Net revenue by Geography | ||||||
| Europe | $285.13M+5.9% | $269.18M+5.2% | $255.78M+6.2% | $240.91M+6.9% | $225.39M+2.4% | |
| Rest of World | $393.24M+3.7% | $379.3M+2.5% | $370M+4.0% | $355.86M+2.7% | $346.36M+2.4% | |
| United States | $755.09M+2.1% | $739.57M+2.3% | $723.18M+1.5% | $712.56M+1.3% | $703.63M+1.2% | |
| Property, Plant and Equipment, Net by Geography | ||||||
| Europe | $540.14M+10.7% | $487.95M+12.2% | $435.04M+10.1% | $394.99M+7.2% | $368.33M+5.1% | |
| Rest of World | $61.45M+8.9% | $56.46M+9.9% | $51.35M+18.9% | $43.18M+25.0% | $34.54M+19.5% | |
| United States | $310.43M+7.1% | $289.81M+5.2% | $275.48M+0.4% | $274.51M+0.8% | $272.45M+0.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LivaNova break its business down?
- LivaNova (LIVN) reports net revenue by business across 2 parts — Cardiopulmonary and Neuromodulation. Each is extracted from the segment footnotes and tracked over time.
- Where does LivaNova's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LivaNova's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.